- Home
- REGN vs MRNA Comparison
REGN vs MRNA Comparison
Compare REGN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | MRNA |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 61.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | REGN | MRNA |
|---|---|---|
| Price | $827.26 | $144.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 12 |
| Target Price | ★ $830.16 | $34.27 |
| AVG Volume (30 Days) | 565.1K | ★ 28.4M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | 8.19 | ★ 21.77 |
| EPS | ★ 18.95 | N/A |
| Revenue | $5,872,227,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $12.45 | $9.36 |
| Revenue Next Year | $10.13 | $15.43 |
| P/E Ratio | $44.35 | ★ N/A |
| Revenue Growth | ★ 20.82 | 4.29 |
| 52 Week Low | $541.00 | $22.28 |
| 52 Week High | $859.34 | $176.66 |
Technical Indicators
Market Signals| Indicator | REGN | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 63.40 |
| Support Level | $732.04 | $43.35 |
| Resistance Level | $847.00 | $176.66 |
| Average True Range (ATR) | 19.34 | 16.22 |
| MACD | -3.02 | 1.79 |
| Stochastic Oscillator | 76.33 | 72.14 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.